Virodhamine is an endogenous cannabinoid that regulates neurotransmission through activation of cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptors and an agonist of CB2 receptors. Virodhamine induces megakaryocyte differentiation by triggering MAPK signalling and generating ROS. Virodhamine can be Virodhamine has been used in the study of various neurological diseases such as Alzheimer's disease and Parkinson's disease[1][2].At a concentration of 50 nM, treating for 72 hours, Virodhamine increases adhesion, membrane expansion and nucleus size. At concentrations in the range of 10-40 μM for 72 h, Virodhamine increases the expression levels of CD61 and TRPV1. Virodhamine inhibits cell proliferation in megakaryocytes and significantly increases the proportion of hyperploid cells[1].
Virodhamine 动物研究
Animal study
Virodhamine repaired nicotine (0.8 mg/kg) and immobilization stress-induced anxiety when administered once intraperitoneally at doses of 1-10 mg/kg. Dose of 5 mg/kg significantly repaired working memory impairment-like behaviours, and dose of 10 mg/kg was significantly anxiolytic-like[2].
搜索
